Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Rhea-AI Summary

Silexion Therapeutics (NASDAQ:SLXN) said management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit in Boston on Jan 27-29, 2026. Company representatives will hold one-on-one meetings with investors and partners by arrangement through Investor Relations. Silexion is developing SIL204, a next‑generation siRNA therapy targeting mutated KRAS oncogenes, and plans to enter a Phase 2/3 clinical study in locally advanced pancreatic cancer in mid‑2026. The company is an official partner of the 2026 summit.

News Market Reaction

-5.80%

1 alert

-5.80% News Effect

-$393K Valuation Impact

$6M Market Cap

0.7x Rel. Volume

On the day this news was published, SLXN declined 5.80%, reflecting a notable negative market reaction. This price movement removed approximately $393K from the company's valuation, bringing the market cap to $6M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Net loss: $7.5 million Cash and equivalents: $9.243 million ATM program size: $13.17 million +5 more

8 metrics

Net loss $7.5 million Nine months ended Sep 30, 2025 (10-Q)

Cash and equivalents $9.243 million As of Sep 30, 2025 (10-Q)

ATM program size $13.17 million At-the-market offering capacity (10-Q)

Primary S-3 shelf $100 million Effective shelf capacity disclosed in 10-Q

Tumor inhibition >90% Preclinical KRAS-mutant tumor models for SIL204 (CEO letter)

KRAS mutations covered 8 mutations Validated activity across 8 KRAS mutations (CEO letter)

Cancer cell inhibition 99.7% Preclinical data in KRAS-mutant models (Israel CTA press release)

Warrant exercise proceeds $4.9 million Potential cash if 344,063 registered warrants exercised (S-3 resale)

Market Reality Check

Price: $2.04 Vol: Volume 16,154 is about 0....

low vol

$2.04 Last Close

Volume Volume 16,154 is about 0.28x the 20-day average of 58,273, indicating light trading. low

Technical Shares at $2.24 are trading below the 200-day MA of $7.80.

Peers on Argus

Peers show mixed moves: GLTO up 15.54%, QLGN up 7.72%, DRMA up 2.36%, while BDRX...

Peers show mixed moves: GLTO up 15.54%, QLGN up 7.72%, DRMA up 2.36%, while BDRX and ENTO are down 3.49% and 5.68%, respectively. This pattern does not indicate a unified sector move around this conference-focused headline.

Historical Context

5 past events · Latest: Jan 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	CEO shareholder letter	Positive	-4.1%	Outlined 2025 achievements, financing, and 2026 clinical milestones for SIL204.
Dec 16	Clinical trial filing	Positive	+1.2%	Submitted Phase 2/3 trial application in Israel for SIL204 in pancreatic cancer.
Dec 02	Regulatory feedback	Positive	-7.6%	Received positive BfArM advice on Phase 2/3 pancreatic cancer trial design.
Nov 26	Investor conference	Positive	+20.4%	Announced Noble Capital Markets conference presentation and 1-on-1 meetings.
Nov 25	Toxicology completion	Positive	+7.6%	Reported successful SIL204 toxicology studies supporting planned Phase 2/3 trial.

Pattern Detected

Recent positive operational and clinical updates sometimes saw negative or muted reactions, while some IR-focused events produced strong upside moves.

Recent Company History

Over the last few months, Silexion reported multiple milestones around SIL204, including completion of two-species toxicology with no systemic organ toxicity and positive BfArM feedback supporting a planned Phase 2/3 trial in pancreatic cancer. The company also submitted a Phase 2/3 clinical trial application in Israel targeting a Q2 2026 start and highlighted >90% tumor inhibition and validated activity against 8 KRAS mutations. Investor reactions have been mixed, with both selloffs and rallies on generally constructive news, suggesting inconsistent sentiment.

Regulatory & Risk Context

Active S-3 Shelf · $4.9 million

Shelf Active

Active S-3 Shelf Registration 2025-10-31

$4.9 million registered capacity

An effective resale registration on Form S-3 filed on Oct 31, 2025 covers up to 1,292,348 ordinary shares and 372 warrants for selling securityholders. The company will not receive proceeds from share resales but may receive up to $4.9 million only if 344,063 registered warrants are exercised for cash.

Market Pulse Summary

The stock moved -5.8% in the session following this news. A negative reaction despite an innocuous c...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite an innocuous conference announcement would fit prior episodes where constructive news coincided with selling, as seen after some regulatory and data milestones. Persistent operating losses and existing financing facilities, including shelf and at-the-market programs, may keep dilution concerns in focus. Historical patterns of sharp downside moves following positive updates suggest that sentiment has been fragile and prone to reversals.

Key Terms

rnai-based therapeutics, rnai, sirna, oncogenes, +3 more

7 terms

rnai-based therapeutics medical

"The 7th RNAi-Based Therapeutics Summit is the industry's premier forum..."

RNAi-based therapeutics are medicines that use small pieces of genetic material to selectively switch off specific genes that cause or contribute to disease; think of them as targeted silencers that stop a faulty instruction in a cell’s blueprint from being carried out. They matter to investors because they represent a new way to treat conditions that conventional drugs can’t reach, offering high potential reward if successful but also carrying development, delivery and regulatory risks that can sharply affect a company’s value.

rnai medical

"forum inviting drug developers to discuss RNA-based therapeutics..."

RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.

sirna medical

"Silexion is developing SIL204, a next-generation siRNA therapy..."

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

oncogenes medical

"designed to silence mutated KRAS oncogenes - the most common..."

Oncogenes are genes that, when changed or overly active, push cells to grow and divide uncontrollably — like a gas pedal stuck down in a car. They matter to investors because they are common targets for cancer tests and drugs; knowing whether a tumor is driven by an oncogene can determine whether a therapy will work, shape clinical trial outcomes, regulatory approval chances and potential market size for diagnostics and treatments.

kras medical

"designed to silence mutated KRAS oncogenes - the most common..."

KRAS is a gene that makes a protein acting like a switch to control cell growth; certain changes (mutations) can lock that switch on and drive uncontrolled cell multiplication, which is a common cause of many cancers. Investors care because drugs or tests targeting KRAS mutations can create large markets or avoidable risks depending on trial results and regulatory decisions, much like a key product feature deciding a gadget’s commercial success.

phase 2/3 regulatory

"SIL204 is planned to enter a Phase 2/3 clinical study program..."

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

pancreatic cancer medical

"clinical study program in locally advanced pancreatic cancer in mid 2026."

Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming a tumor that disrupts the organ’s role in digestion and blood-sugar regulation; because it often spreads early and is hard to detect, outcomes tend to be poor. For investors, it matters because diagnosis rates, treatment advances, drug approvals, and clinical trial results can strongly affect the value of biotech and healthcare companies—think of a breakthrough therapy as a new part that could fix a failing engine and reshape market expectations.

AI-generated analysis. Not financial advice.

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.  

The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes - the most common oncogenic driver in human cancers. SIL204 is planned to enter a Phase 2/3 clinical study program in locally advanced pancreatic cancer in mid 2026.

Silexion management will host one-on-one meetings during the summit. Interested parties should contact the Company’s Investor Relations representatives who can arrange such meetings.

Silexion is pleased to be an official partner of the RNAi-Based Therapeutics Summit for 2026.

About Silexion Therapuetics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

FAQ

When will Silexion (SLXN) attend the 7th RNAi-Based Therapeutics Summit?

Silexion management will attend the summit in Boston on January 27–29, 2026.

Will Silexion CEO Ilan Hadar be at the RNAi summit (SLXN)?

Yes. The company said CEO Ilan Hadar will attend and meet one‑on‑one with interested parties.

What program update did Silexion (SLXN) provide about SIL204 at the summit?

Silexion noted that SIL204 is planned to enter a Phase 2/3 clinical study in locally advanced pancreatic cancer in mid‑2026.

How can investors arrange meetings with Silexion (SLXN) at the January 2026 summit?

Investors should contact Silexion’s Investor Relations to arrange one‑on‑one meetings during the event.

What is SIL204 and which target does it address for Silexion (SLXN)?

SIL204 is a next‑generation siRNA therapy designed to silence mutated KRAS oncogenes, a common oncogenic driver in human cancers.